View ValuationRenata 将来の成長Future 基準チェック /46Renata利益と収益がそれぞれ年間30%と12.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.8% 29.3%なると予測されています。主要情報30.0%収益成長率29.26%EPS成長率Pharmaceuticals 収益成長14.9%収益成長率12.9%将来の株主資本利益率14.75%アナリストカバレッジLow最終更新日30 Apr 2026今後の成長に関する最新情報Price Target Changed • May 20Price target decreased by 11% to ৳615Down from ৳690, the current price target is an average from 2 analysts. New target price is 52% above last closing price of ৳406. Stock is down 16% over the past year. The company is forecast to post earnings per share of ৳24.52 for next year compared to ৳19.36 last year.Price Target Changed • Mar 15Price target decreased by 11% to ৳1,091Down from ৳1,224, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,218. Stock is down 4.2% over the past year. The company is forecast to post earnings per share of ৳36.30 for next year compared to ৳44.56 last year.Price Target Changed • Feb 05Price target increased to ৳1,276Up from ৳1,142, the current price target is an average from 3 analysts. New target price is 5.2% below last closing price of ৳1,346. Stock is up 26% over the past year. The company is forecast to post earnings per share of ৳54.17 for next year compared to ৳47.22 last year.Price Target Changed • Jul 05Price target increased to ৳1,185Up from ৳1,058, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,320. Stock is up 41% over the past year.Price Target Changed • Jan 23Price target raised to ৳1,058Up from ৳932, the current price target is an average from 3 analysts. The new target price is 8.4% below the current share price of ৳1,155. As of last close, the stock is up 14% over the past year.Price Target Changed • Nov 28Price target raised to ৳1,038Up from ৳932, the current price target is an average from 3 analysts. The new target price is close to the current share price of ৳1,052. As of last close, the stock is down 0.7% over the past year.すべての更新を表示Recent updatesPrice Target Changed • May 20Price target decreased by 11% to ৳615Down from ৳690, the current price target is an average from 2 analysts. New target price is 52% above last closing price of ৳406. Stock is down 16% over the past year. The company is forecast to post earnings per share of ৳24.52 for next year compared to ৳19.36 last year.Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Sajeda Amin was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 22Renata PLC to Report Q3, 2026 Results on Apr 29, 2026Renata PLC announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 20Renata PLC to Report Q2, 2026 Results on Jan 29, 2026Renata PLC announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Jan 09Renata PLC Secures Turkish Regulatory Approval for Flagship FacilityRenata PLC informed that they have received regulatory approval from the Turkish Medicines and Medical Devices Agency for its Rajendrapur General Facility, qualifying the site to register and supply oral solid dosage pharmaceutical products (tablets and capsules) in Turkey. Turkey represents a strategically important market for Renata, positioned at the intersection of Europe and the Middle East. This approval further strengthens the Company's international footprint and complements the facility's existing approvals from other stringent regulatory authorities, including EU GMP and US FDA, reaffirming Renata's commitment to global quality standards. The Company also anticipates regulatory approval of Amantadine in Turkey within the next year, which is expected to further support Renata's commercial expansion in the region.お知らせ • Oct 29Renata PLC announces Annual dividend, payable on January 19, 2026Renata PLC announced Annual dividend of BDT 5.5000 per share payable on January 19, 2026, ex-date on November 18, 2025 and record date on November 17, 2025.お知らせ • Oct 28Renata PLC, Annual General Meeting, Dec 20, 2025Renata PLC, Annual General Meeting, Dec 20, 2025, at 11:30 Central Asia Standard Time.お知らせ • Oct 16+ 1 more updateRenata PLC to Report Q1, 2026 Results on Oct 27, 2025Renata PLC announced that they will report Q1, 2026 results on Oct 27, 2025お知らせ • May 12Esperion Reaches Settlement Agreement with Anda Filer Not to Market Generic Version of Nexletol® (Bempedoic Acid) Prior to April 19, 2040Esperion announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Limited (along with an affiliate); Dr. Reddy’s Laboratories Inc. (along with an affiliate); Hetero USA Inc. (along with affiliates); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.お知らせ • Apr 23Renata PLC to Report Q3, 2025 Results on Apr 30, 2025Renata PLC announced that they will report Q3, 2025 results on Apr 30, 2025お知らせ • Jan 20Renata PLC to Report Q2, 2025 Results on Jan 25, 2025Renata PLC announced that they will report Q2, 2025 results on Jan 25, 2025Reported Earnings • Nov 17First quarter 2025 earnings released: EPS: ৳5.19 (vs ৳8.89 in 1Q 2024)First quarter 2025 results: EPS: ৳5.19 (down from ৳8.89 in 1Q 2024). Revenue: ৳10.2b (up 7.7% from 1Q 2024). Net income: ৳595.0m (down 42% from 1Q 2024). Profit margin: 5.9% (down from 11% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (11% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (6.3% net profit margin).お知らせ • Nov 08Renata PLC to Report Q1, 2025 Results on Nov 13, 2024Renata PLC announced that they will report Q1, 2025 results on Nov 13, 2024Buy Or Sell Opportunity • Oct 29Now 20% overvaluedOver the last 90 days, the stock has fallen 8.3% to ৳651. The fair value is estimated to be ৳542, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.6% over the last 3 years. Earnings per share has declined by 29%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 29% per annum over the same time period.Upcoming Dividend • Oct 15Upcoming dividend of ৳9.20 per shareEligible shareholders must have bought the stock before 22 October 2024. Payment date: 05 January 2025. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (3.4%).お知らせ • Oct 07Renata PLC Launches Two New Products in the UK MarketRenata PLC has informed that it has successfully dispatched its first shipment of Sertraline 100mg and Propylthiouracil 50mg tablets to the UK market. These high-quality products are manufactured at their UK MHRA-approved facility in Rajendrapur, Bangladesh. Under Renata UK's branding and in partnership with a local commercialization team, these medications will soon be available to UK consumers. In Bangladesh, these same products are known under their local brand names, Seronex (Sertraline) and PTU (Propylthiouracil), solidifying Renata's commitment to delivering excellence both locally and globally.お知らせ • Sep 30Renata PLC, Annual General Meeting, Dec 05, 2024Renata PLC, Annual General Meeting, Dec 05, 2024, at 11:30 Central Asia Standard Time.お知らせ • Sep 18Renata PLC to Report Fiscal Year 2024 Results on Sep 28, 2024Renata PLC announced that they will report fiscal year 2024 results on Sep 28, 2024Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ৳724, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 33% over the past three years.Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳6,330 (vs ৳5.06 in 3Q 2023)Third quarter 2024 results: EPS: ৳6,330 (up from ৳5.06 in 3Q 2023). Revenue: ৳9.21b (up 9.1% from 3Q 2023). Net income: ৳726.2m (up 25% from 3Q 2023). Profit margin: 7.9% (up from 6.9% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.お知らせ • Apr 24Renata PLC to Report Q3, 2024 Results on Apr 29, 2024Renata PLC announced that they will report Q3, 2024 results on Apr 29, 2024Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳1,013, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 4.8% over the past three years.New Risk • Jan 27New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risk Profit margins are more than 30% lower than last year (6.0% net profit margin).お知らせ • Jan 22Renata Limited to Report Q2, 2024 Results on Jan 27, 2024Renata Limited announced that they will report Q2, 2024 results on Jan 27, 2024Upcoming Dividend • Nov 07Upcoming dividend of ৳6.25 per share at 0.5% yieldEligible shareholders must have bought the stock before 13 November 2023. Payment date: 08 January 2024. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (2.5%).Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: ৳5.06 (vs ৳11.92 in 3Q 2022)Third quarter 2023 results: EPS: ৳5.06 (down from ৳11.92 in 3Q 2022). Revenue: ৳8.45b (up 12% from 3Q 2022). Net income: ৳580.8m (down 57% from 3Q 2022). Profit margin: 6.9% (down from 18% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 23Renata Limited Proposes Cash Dividend for the Year Ended June 30, 2023Renata Limited proposed 62.5% Cash Dividend for the year ended June 30, 2023 at its AGM to be held on December 9, 2023.お知らせ • Oct 13Renata Limited to Report Q4, 2023 Results on Oct 21, 2023Renata Limited announced that they will report Q4, 2023 results on Oct 21, 2023Price Target Changed • Mar 15Price target decreased by 11% to ৳1,091Down from ৳1,224, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,218. Stock is down 4.2% over the past year. The company is forecast to post earnings per share of ৳36.30 for next year compared to ৳44.56 last year.Reported Earnings • Feb 04Second quarter 2023 earnings released: EPS: ৳7.66 (vs ৳11.89 in 2Q 2022)Second quarter 2023 results: EPS: ৳7.66 (down from ৳11.89 in 2Q 2022). Revenue: ৳7.58b (flat on 2Q 2022). Net income: ৳878.8m (down 36% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Ejaj Ahmad was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Nov 06Upcoming dividend of ৳14.00 per shareEligible shareholders must have bought the stock before 13 November 2022. Payment date: 16 January 2023. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Bangladeshi dividend payers (3.7%). Lower than average of industry peers (2.4%).お知らせ • Oct 24Renata Limited Recommends Dividend for the Year Ended June 30, 2022The Board of Directors of Renata Limited has recommended 140% cash dividend for the year ended June 30, 2022.Reported Earnings • May 02Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: ৳12.76 (up from ৳11.55 in 3Q 2021). Revenue: ৳7.71b (up 19% from 3Q 2021). Net income: ৳1.37b (up 11% from 3Q 2021). Profit margin: 18% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 9.6%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 16% per year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Ejaj Ahmad was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Feb 05Price target increased to ৳1,276Up from ৳1,142, the current price target is an average from 3 analysts. New target price is 5.2% below last closing price of ৳1,346. Stock is up 26% over the past year. The company is forecast to post earnings per share of ৳54.17 for next year compared to ৳47.22 last year.Reported Earnings • Feb 01Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: ৳12.73 (up from ৳10.84 in 2Q 2021). Revenue: ৳7.68b (up 7.0% from 2Q 2021). Net income: ৳1.36b (up 17% from 2Q 2021). Profit margin: 18% (up from 16% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.Upcoming Dividend • Nov 09Upcoming dividend of ৳14.50 per shareEligible shareholders must have bought the stock before 16 November 2021. Payment date: 17 January 2022. Trailing yield: 0.9%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (1.8%).Price Target Changed • Jul 05Price target increased to ৳1,185Up from ৳1,058, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,320. Stock is up 41% over the past year.Reported Earnings • May 02Third quarter 2021 earnings released: EPS ৳12.70 (vs ৳10.96 in 3Q 2020)The company reported a solid third quarter result with improved earnings and profit margins, although revenues were flat. Third quarter 2021 results: Revenue: ৳6.50b (flat on 3Q 2020). Net income: ৳1.24b (up 16% from 3Q 2020). Profit margin: 19% (up from 17% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 12% per year.Is New 90 Day High Low • Mar 09New 90-day high: ৳1,182The company is up 10.0% from its price of ৳1,074 on 09 December 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳427 per share.Is New 90 Day High Low • Feb 10New 90-day high: ৳1,177The company is up 11% from its price of ৳1,060 on 12 November 2020. The Bangladeshi market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Pharmaceuticals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳427 per share.Reported Earnings • Feb 02Second quarter 2021 earnings released: EPS ৳11.93 (vs ৳9.84 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ৳7.18b (up 16% from 2Q 2020). Net income: ৳1.16b (up 21% from 2Q 2020). Profit margin: 16% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Price Target Changed • Jan 23Price target raised to ৳1,058Up from ৳932, the current price target is an average from 3 analysts. The new target price is 8.4% below the current share price of ৳1,155. As of last close, the stock is up 14% over the past year.Is New 90 Day High Low • Jan 04New 90-day high: ৳1,143The company is up 9.0% from its price of ৳1,047 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳512 per share.Is New 90 Day High Low • Dec 07New 90-day high: ৳1,091The company is up 2.0% from its price of ৳1,073 on 08 September 2020. The Bangladeshi market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳420 per share.Price Target Changed • Nov 28Price target raised to ৳1,038Up from ৳932, the current price target is an average from 3 analysts. The new target price is close to the current share price of ৳1,052. As of last close, the stock is down 0.7% over the past year.Upcoming Dividend • Nov 10Upcoming Dividend of ৳13.00 Per ShareWill be paid on the 18th of January to those who are registered shareholders by the 17th of November. The trailing yield of 0.8% is below the top quartile of Bangladeshi dividend payers (3.8%), and is lower than industry peers (1.6%).業績と収益の成長予測DSE:RENATA - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202862,4886,331N/A8,61926/30/202755,0834,388N/A5,41726/30/202647,4502,812N/A2,68423/31/202644,9342,7317404,794N/A12/31/202544,2622,5361,3995,784N/A9/30/202544,0322,3681,4146,171N/A6/30/202542,8922,2211394,721N/A3/31/202541,3942,813-1,1954,729N/A12/31/202439,9122,957-3,5382,175N/A9/30/202438,4373,191-4,9321,069N/A6/30/202437,7093,616-3,8662,083N/A3/31/202436,4692,294-2,9411,878N/A12/31/202335,6892,143-2,5812,692N/A9/30/202334,0402,114-3,2202,067N/A6/30/202332,9712,339-3,6852,085N/A3/31/202332,5453,674-6,7071,078N/A12/31/202231,6704,461-8,2831,058N/A9/30/202231,7234,974-7,4802,450N/A6/30/202231,0715,111-7,0903,009N/A3/31/202231,8485,537-5,1673,092N/A12/31/202130,7825,408-2,7793,774N/A9/30/202130,3365,206135,244N/A6/30/202129,9715,062-1034,320N/A3/31/202126,6224,5941,0784,422N/A12/31/202026,5964,4242,0295,096N/A9/30/202025,1154,3387033,719N/A6/30/202024,6754,0122,1024,686N/A3/31/202025,7914,3532,0384,483N/A12/31/201924,2654,114N/A3,111N/A9/30/201924,0393,943N/A4,238N/A6/30/201922,2213,823N/A4,155N/A3/31/201920,6333,452N/A3,957N/A12/31/201820,2823,397N/A3,319N/A9/30/201819,5663,241N/A2,808N/A6/30/201819,0503,106N/A2,652N/A3/31/201818,9253,020N/A2,221N/A12/31/201718,2382,867N/A3,401N/A9/30/201717,7832,818N/A3,638N/A6/30/201716,6452,678N/A3,651N/A3/31/201716,1372,522N/A3,538N/A12/31/201615,4262,446N/A3,829N/A9/30/201615,6442,499N/A3,442N/A6/30/201614,7772,274N/A1,950N/A3/31/201613,5922,145N/A2,252N/A12/31/201513,4252,076N/A1,985N/A9/30/201512,5661,993N/A2,623N/A6/30/201512,2411,902N/A2,193N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RENATAの予測収益成長率 (年間30% ) は 貯蓄率 ( 4.2% ) を上回っています。収益対市場: RENATAの収益 ( 30% ) はBD市場 ( 15.1% ) よりも速いペースで成長すると予測されています。高成長収益: RENATAの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: RENATAの収益 ( 12.9% ) BD市場 ( 11% ) よりも速いペースで成長すると予測されています。高い収益成長: RENATAの収益 ( 12.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RENATAの 自己資本利益率 は、3年後には低くなると予測されています ( 14.8 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 12:30終値2026/05/24 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Renata PLC 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Asif KhanEDGE Research & ConsultingFahad ShaikhEFG-Hermes ResearchNafis ZakiUCB Stock Brokerage Limited
Price Target Changed • May 20Price target decreased by 11% to ৳615Down from ৳690, the current price target is an average from 2 analysts. New target price is 52% above last closing price of ৳406. Stock is down 16% over the past year. The company is forecast to post earnings per share of ৳24.52 for next year compared to ৳19.36 last year.
Price Target Changed • Mar 15Price target decreased by 11% to ৳1,091Down from ৳1,224, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,218. Stock is down 4.2% over the past year. The company is forecast to post earnings per share of ৳36.30 for next year compared to ৳44.56 last year.
Price Target Changed • Feb 05Price target increased to ৳1,276Up from ৳1,142, the current price target is an average from 3 analysts. New target price is 5.2% below last closing price of ৳1,346. Stock is up 26% over the past year. The company is forecast to post earnings per share of ৳54.17 for next year compared to ৳47.22 last year.
Price Target Changed • Jul 05Price target increased to ৳1,185Up from ৳1,058, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,320. Stock is up 41% over the past year.
Price Target Changed • Jan 23Price target raised to ৳1,058Up from ৳932, the current price target is an average from 3 analysts. The new target price is 8.4% below the current share price of ৳1,155. As of last close, the stock is up 14% over the past year.
Price Target Changed • Nov 28Price target raised to ৳1,038Up from ৳932, the current price target is an average from 3 analysts. The new target price is close to the current share price of ৳1,052. As of last close, the stock is down 0.7% over the past year.
Price Target Changed • May 20Price target decreased by 11% to ৳615Down from ৳690, the current price target is an average from 2 analysts. New target price is 52% above last closing price of ৳406. Stock is down 16% over the past year. The company is forecast to post earnings per share of ৳24.52 for next year compared to ৳19.36 last year.
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Sajeda Amin was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 22Renata PLC to Report Q3, 2026 Results on Apr 29, 2026Renata PLC announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 20Renata PLC to Report Q2, 2026 Results on Jan 29, 2026Renata PLC announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Jan 09Renata PLC Secures Turkish Regulatory Approval for Flagship FacilityRenata PLC informed that they have received regulatory approval from the Turkish Medicines and Medical Devices Agency for its Rajendrapur General Facility, qualifying the site to register and supply oral solid dosage pharmaceutical products (tablets and capsules) in Turkey. Turkey represents a strategically important market for Renata, positioned at the intersection of Europe and the Middle East. This approval further strengthens the Company's international footprint and complements the facility's existing approvals from other stringent regulatory authorities, including EU GMP and US FDA, reaffirming Renata's commitment to global quality standards. The Company also anticipates regulatory approval of Amantadine in Turkey within the next year, which is expected to further support Renata's commercial expansion in the region.
お知らせ • Oct 29Renata PLC announces Annual dividend, payable on January 19, 2026Renata PLC announced Annual dividend of BDT 5.5000 per share payable on January 19, 2026, ex-date on November 18, 2025 and record date on November 17, 2025.
お知らせ • Oct 28Renata PLC, Annual General Meeting, Dec 20, 2025Renata PLC, Annual General Meeting, Dec 20, 2025, at 11:30 Central Asia Standard Time.
お知らせ • Oct 16+ 1 more updateRenata PLC to Report Q1, 2026 Results on Oct 27, 2025Renata PLC announced that they will report Q1, 2026 results on Oct 27, 2025
お知らせ • May 12Esperion Reaches Settlement Agreement with Anda Filer Not to Market Generic Version of Nexletol® (Bempedoic Acid) Prior to April 19, 2040Esperion announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Limited (along with an affiliate); Dr. Reddy’s Laboratories Inc. (along with an affiliate); Hetero USA Inc. (along with affiliates); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.
お知らせ • Apr 23Renata PLC to Report Q3, 2025 Results on Apr 30, 2025Renata PLC announced that they will report Q3, 2025 results on Apr 30, 2025
お知らせ • Jan 20Renata PLC to Report Q2, 2025 Results on Jan 25, 2025Renata PLC announced that they will report Q2, 2025 results on Jan 25, 2025
Reported Earnings • Nov 17First quarter 2025 earnings released: EPS: ৳5.19 (vs ৳8.89 in 1Q 2024)First quarter 2025 results: EPS: ৳5.19 (down from ৳8.89 in 1Q 2024). Revenue: ৳10.2b (up 7.7% from 1Q 2024). Net income: ৳595.0m (down 42% from 1Q 2024). Profit margin: 5.9% (down from 11% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (11% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (6.3% net profit margin).
お知らせ • Nov 08Renata PLC to Report Q1, 2025 Results on Nov 13, 2024Renata PLC announced that they will report Q1, 2025 results on Nov 13, 2024
Buy Or Sell Opportunity • Oct 29Now 20% overvaluedOver the last 90 days, the stock has fallen 8.3% to ৳651. The fair value is estimated to be ৳542, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.6% over the last 3 years. Earnings per share has declined by 29%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 29% per annum over the same time period.
Upcoming Dividend • Oct 15Upcoming dividend of ৳9.20 per shareEligible shareholders must have bought the stock before 22 October 2024. Payment date: 05 January 2025. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (3.4%).
お知らせ • Oct 07Renata PLC Launches Two New Products in the UK MarketRenata PLC has informed that it has successfully dispatched its first shipment of Sertraline 100mg and Propylthiouracil 50mg tablets to the UK market. These high-quality products are manufactured at their UK MHRA-approved facility in Rajendrapur, Bangladesh. Under Renata UK's branding and in partnership with a local commercialization team, these medications will soon be available to UK consumers. In Bangladesh, these same products are known under their local brand names, Seronex (Sertraline) and PTU (Propylthiouracil), solidifying Renata's commitment to delivering excellence both locally and globally.
お知らせ • Sep 30Renata PLC, Annual General Meeting, Dec 05, 2024Renata PLC, Annual General Meeting, Dec 05, 2024, at 11:30 Central Asia Standard Time.
お知らせ • Sep 18Renata PLC to Report Fiscal Year 2024 Results on Sep 28, 2024Renata PLC announced that they will report fiscal year 2024 results on Sep 28, 2024
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ৳724, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 33% over the past three years.
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳6,330 (vs ৳5.06 in 3Q 2023)Third quarter 2024 results: EPS: ৳6,330 (up from ৳5.06 in 3Q 2023). Revenue: ৳9.21b (up 9.1% from 3Q 2023). Net income: ৳726.2m (up 25% from 3Q 2023). Profit margin: 7.9% (up from 6.9% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 24Renata PLC to Report Q3, 2024 Results on Apr 29, 2024Renata PLC announced that they will report Q3, 2024 results on Apr 29, 2024
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳1,013, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 4.8% over the past three years.
New Risk • Jan 27New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risk Profit margins are more than 30% lower than last year (6.0% net profit margin).
お知らせ • Jan 22Renata Limited to Report Q2, 2024 Results on Jan 27, 2024Renata Limited announced that they will report Q2, 2024 results on Jan 27, 2024
Upcoming Dividend • Nov 07Upcoming dividend of ৳6.25 per share at 0.5% yieldEligible shareholders must have bought the stock before 13 November 2023. Payment date: 08 January 2024. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (2.5%).
Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: ৳5.06 (vs ৳11.92 in 3Q 2022)Third quarter 2023 results: EPS: ৳5.06 (down from ৳11.92 in 3Q 2022). Revenue: ৳8.45b (up 12% from 3Q 2022). Net income: ৳580.8m (down 57% from 3Q 2022). Profit margin: 6.9% (down from 18% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 23Renata Limited Proposes Cash Dividend for the Year Ended June 30, 2023Renata Limited proposed 62.5% Cash Dividend for the year ended June 30, 2023 at its AGM to be held on December 9, 2023.
お知らせ • Oct 13Renata Limited to Report Q4, 2023 Results on Oct 21, 2023Renata Limited announced that they will report Q4, 2023 results on Oct 21, 2023
Price Target Changed • Mar 15Price target decreased by 11% to ৳1,091Down from ৳1,224, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,218. Stock is down 4.2% over the past year. The company is forecast to post earnings per share of ৳36.30 for next year compared to ৳44.56 last year.
Reported Earnings • Feb 04Second quarter 2023 earnings released: EPS: ৳7.66 (vs ৳11.89 in 2Q 2022)Second quarter 2023 results: EPS: ৳7.66 (down from ৳11.89 in 2Q 2022). Revenue: ৳7.58b (flat on 2Q 2022). Net income: ৳878.8m (down 36% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Ejaj Ahmad was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Nov 06Upcoming dividend of ৳14.00 per shareEligible shareholders must have bought the stock before 13 November 2022. Payment date: 16 January 2023. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Bangladeshi dividend payers (3.7%). Lower than average of industry peers (2.4%).
お知らせ • Oct 24Renata Limited Recommends Dividend for the Year Ended June 30, 2022The Board of Directors of Renata Limited has recommended 140% cash dividend for the year ended June 30, 2022.
Reported Earnings • May 02Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: ৳12.76 (up from ৳11.55 in 3Q 2021). Revenue: ৳7.71b (up 19% from 3Q 2021). Net income: ৳1.37b (up 11% from 3Q 2021). Profit margin: 18% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 9.6%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 16% per year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Ejaj Ahmad was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Feb 05Price target increased to ৳1,276Up from ৳1,142, the current price target is an average from 3 analysts. New target price is 5.2% below last closing price of ৳1,346. Stock is up 26% over the past year. The company is forecast to post earnings per share of ৳54.17 for next year compared to ৳47.22 last year.
Reported Earnings • Feb 01Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: ৳12.73 (up from ৳10.84 in 2Q 2021). Revenue: ৳7.68b (up 7.0% from 2Q 2021). Net income: ৳1.36b (up 17% from 2Q 2021). Profit margin: 18% (up from 16% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.
Upcoming Dividend • Nov 09Upcoming dividend of ৳14.50 per shareEligible shareholders must have bought the stock before 16 November 2021. Payment date: 17 January 2022. Trailing yield: 0.9%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (1.8%).
Price Target Changed • Jul 05Price target increased to ৳1,185Up from ৳1,058, the current price target is an average from 2 analysts. New target price is 10% below last closing price of ৳1,320. Stock is up 41% over the past year.
Reported Earnings • May 02Third quarter 2021 earnings released: EPS ৳12.70 (vs ৳10.96 in 3Q 2020)The company reported a solid third quarter result with improved earnings and profit margins, although revenues were flat. Third quarter 2021 results: Revenue: ৳6.50b (flat on 3Q 2020). Net income: ৳1.24b (up 16% from 3Q 2020). Profit margin: 19% (up from 17% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 12% per year.
Is New 90 Day High Low • Mar 09New 90-day high: ৳1,182The company is up 10.0% from its price of ৳1,074 on 09 December 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳427 per share.
Is New 90 Day High Low • Feb 10New 90-day high: ৳1,177The company is up 11% from its price of ৳1,060 on 12 November 2020. The Bangladeshi market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Pharmaceuticals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳427 per share.
Reported Earnings • Feb 02Second quarter 2021 earnings released: EPS ৳11.93 (vs ৳9.84 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ৳7.18b (up 16% from 2Q 2020). Net income: ৳1.16b (up 21% from 2Q 2020). Profit margin: 16% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Jan 23Price target raised to ৳1,058Up from ৳932, the current price target is an average from 3 analysts. The new target price is 8.4% below the current share price of ৳1,155. As of last close, the stock is up 14% over the past year.
Is New 90 Day High Low • Jan 04New 90-day high: ৳1,143The company is up 9.0% from its price of ৳1,047 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳512 per share.
Is New 90 Day High Low • Dec 07New 90-day high: ৳1,091The company is up 2.0% from its price of ৳1,073 on 08 September 2020. The Bangladeshi market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳420 per share.
Price Target Changed • Nov 28Price target raised to ৳1,038Up from ৳932, the current price target is an average from 3 analysts. The new target price is close to the current share price of ৳1,052. As of last close, the stock is down 0.7% over the past year.
Upcoming Dividend • Nov 10Upcoming Dividend of ৳13.00 Per ShareWill be paid on the 18th of January to those who are registered shareholders by the 17th of November. The trailing yield of 0.8% is below the top quartile of Bangladeshi dividend payers (3.8%), and is lower than industry peers (1.6%).